Table 2

Comparison of Baseline Characteristics in Women Randomized to Digoxin With and Without a Measurement of SDC at Their Week Four Visit

CharacteristicSDC DoneSDC Not Donep Value
n411338
Age (yrs)64 ± 1265 ± 130.181
Race (non-white) (%)19170.535
Prior MI (%)54590.210
Current angina (%)26300.256
Hypertension (%)55540.933
Ischemic etiology (%)63650.668
Diabetes (%)30360.140
Previous digoxin use, yes (%)52410.002
NYHA functional class2.3 ± 0.72.4 ± 0.70.077
BMI (kg/m2)27 ± 6.427 ± 6.40.634
LVEF (U)30 ± 9.031 ± 8.60.075
Duration of CHF (months)31 ± 3724 ± 340.009†
SBP (mm Hg)129 ± 21127 ± 200.359
DBP (mm Hg)75 ± 1174 ± 120.036†
Heart rate (beats/min)81 ± 1282 ± 130.497
CT ratio0.56 ± 0.080.57 ± 0.080.500
CHF score (U)12.4 ± 5.112.4 ± 5.20.895
eGFR (ml/min/1.73 m2)61 ± 2157 ± 200.012
ACE inhibitor96930.197
Diuretic88870.740
Nitrate43430.854
Vasodilator3.23.60.769

Results shown as mean ± SD where appropriate.

Abbreviations as in Table 1.

  • Present in original model of independent risk factors for both mortality and combined end point (Table 4); †not present in model of independent risk factors—forced to account for differences between SDC yes and no.